CD274 and non-small cell lung carcinoma: After that, pembrolizumab, developed by Merck & Co, was approved by the FDA for the first-line treatment of patients with metastatic NSCLC in 2016.1312 Different from nivolumab, the prescription of pembrolizumab requires confirmed PD-L1 overexpression on tumors.